COS Funding Opportunities Search

COS Funding Opportunities™

COS Unique Id:	113358
Title:	FDA Small Scientific Conference Program (R13/U13)
Sponsor:	Department of Health and Human Services (HHS) Food and Drug Administration (FDA)
Sponsor Type:	Federal, U.S.
Deadline:	July 15, 2008 October 15, 2008 January 15, 2009 April 15, 2009
Deadline Note:	The opening date is May 1, 2008. This opportunity will expire on July 16, 2011. For some conference grant applications, the time from submission to funding is shorter than the regular cycle. A second level of review by a board or council is not required for applications with budgets less than $50,000 total costs; therefore, funding selections may be made sooner than the cycle indicated. Applicants may submit more than one application, provided they propose scientifically distinct conferences or scientific meetings. FDA centers will not accept multiple applications for a single scientific meeting. Advance permission to submit an application must be requested early in the process and no later than six weeks before the application submission date. Most centers will accept applications for up to five years when a series of annual or biannual meetings is proposed by a permanently sponsoring organization. Support for meetings held on a less frequent schedule must be applied for individually.
Amount Note:	This FOA will use the FDA conference grant (R13/U13) award mechanism. The FDA U13 is a cooperative agreement award mechanism. Because the nature and scope of the proposed activities will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total project period for an application requesting support may not exceed five years. This program does not require cost sharing.
Eligibility:	Eligible organizations include for-profit and nonprofit organizations; public or private institutions, such as universities, colleges, hospitals, and laboratories; units of state and local governments; eligible agencies of the federal government; domestic institutions and organizations; and faith-based or community-based organizations. Foreign institutions are not eligible to apply for conference grant support. An international conference can be supported through the U.S. representative organization of an established international scientific or professional society.
Citizenship or Residency:	United States
Activity Location:	Unrestricted
Requirements:	Small Business Ph.D./M.D./Other Professional Commercial Government Nonprofit Academic Institution
Abstract:	The FDA recognizes the value of supporting high quality conferences and scientific meetings that are relevant to its scientific mission and to the public health. A conference or scientific meeting is defined as a gathering, symposium, seminar, scientific meeting, workshop, or any other organized, formal meeting where persons assemble to coordinate, exchange, and disseminate information or to explore or clarify a defined subject, problem, or area of knowledge. Support of such meetings is contingent on the fiscal and programmatic interests and priorities of the individual centers, which are linked to the FDA Grant website (http://www.fda.gov/). Therefore, a conference grant application is required to contain a letter from the appropriate FDA staff documenting advance permission. Investigators are urged to initiate contact well in advance of the application receipt date. Agreement to accept an application does not guarantee funding.
Contact Name:	Michelle Hawley, Acting Team Leader
Contact Address:	Grants and Assistance Agreements Team Division of Acquisition Support and Grants
Contact Country:	United States
Contact Phone:	+1 (301) 827-1991
Contact Email:	Michelle.Hawley@fda.hhs.gov
URL for more information:	http://grants1.nih.gov/grants/guide/rfa-files/RFA-FD-08-003.html
Date Last Revised:	April 9, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=113358
Keywords:	Agriculture and Food Sciences Energy Sciences Engineering Natural and Physical Sciences, Mathematics and Technology
Sponsor Reference No:	RFA-FD-08-003
Funding Type:	Collaboration or Cooperative Agreement Meeting or Conference or Seminar

COS Unique Id:	113372
Title:	Genetic Screens to Enhance Zebrafish Research (R01)
Sponsor:	Department of Health and Human Services (HHS) National Institutes of Health (NIH)
Sponsor Type:	Federal, U.S.
Deadline:	September 24, 2008 September 24, 2009 September 24, 2010
Deadline Note:	The opening date is August 24, 2008. Non-required letters of intent are due August 25, 2008; August 25, 2009; and August 25, 2010. This opportunity will expire on September 25, 2010. An individual principal investigator may submit only one application per year in response to this announcement. There is no limit to the number of different applications that an applicant institution may submit.
Amount Note:	This FOA will utilize the NIH Research Project Grant (R01) grant mechanism. Budgets for under $500,000 direct costs per year and project duration of up to five years may be requested. There is no special set aside of funds for applications submitted in response to this announcement. This program does not require cost sharing.
Eligibility:	Eligible applicants include institutions of higher education; nonprofits, for-profits, and small businesses; state and local governments; eligible agencies of the federal government; and non-domestic organizations.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Small Business Ph.D./M.D./Other Professional Commercial Government Nonprofit Academic Institution
Abstract:	This FOA encourages investigator-initiated applications designed to exploit the power of the zebrafish as a vertebrate model for biomedical and behavioral research. Applications proposing to develop new genetic screens of high priority to the zebrafish community that will advance the detection and characterization of genes, pathways, and phenotypes of interest in development and aging, organ formation, neural processes, behavior, sensory processes, physiological processes, and disease processes are welcome. Proposals responsive to this FOA will include, but are not limited to, the following: 1. The development and/or application of novel screens for mutants - These may be refinements of phenotypic analyses preparatory to screening, or phenotypic screens based on observations of altered morphology, physiology, or behavior. 2. Screens identifying novel developmental genes and pathways, including those mediating sensitivity or resistance to environmental teratogens 3. Screens identifying genetic modifiers of genes and/or gene variants affecting pathways of interest 4. Screens analyzing the genetic basis of adult phenotypes including behavior, aging, organ disease, cancer, and responses to environmental toxicants, alcohol, and drugs of abuse 5. Development of high throughput small molecule screens (including nanomaterials) Participating organizations include Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Deafness and Other communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), and National Institute of Neurological Disorders and Stroke (NINDS).
Contact Name:	Dr. Lorette Javois
Contact Address:	Center for Developmental Biology and Perinatal Medicine, NICHD 6100 Executive Boulevard, Room 4B01, MSC 7510
Contact City:	Bethesda
Contact State:	Maryland
Contact Zip:	20892-7510
Contact Country:	United States
Contact Phone:	+1 (301) 496-5541
Contact Fax:	+1 (301) 480-0303
Contact Email:	lj89j@nih.gov
URL for more information:	http://grants1.nih.gov/grants/guide/pa-files/PAR-08-138.html
Date Last Revised:	April 9, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=113372
Keywords:	Animal Models
Sponsor Reference No:	PAR-08-138
Funding Type:	Research

COS Unique Id:	113373
Title:	Enhancing Zebrafish Research with Research Tools and Techniques (R01)
Sponsor:	Department of Health and Human Services (HHS) National Institutes of Health (NIH)
Sponsor Type:	Federal, U.S.
Deadline:	September 17, 2008 September 17, 2009 September 17, 2010
Deadline Note:	The opening date is August 17, 2008. Non-required letters of intent are due August 17, 2008; August 17, 2009; and August 17, 2010. This opportunity will expire on September 18, 2010. An individual principal investigator may submit only one application per year in response to this announcement. There is no limit to the number of different applications that an applicant institution may submit.
Amount Note:	This FOA will utilize the NIH Research Project Grant (R01) grant mechanism. Budgets for under $500,000 direct costs per year and project duration of up to five years may be requested. There is no special set aside of funds for applications submitted in response to this announcement. This program does not require cost sharing.
Eligibility:	Eligible applicants include institutions of higher education; nonprofits, for-profits, and small businesses; state and local governments; eligible agencies of the federal government; and non-domestic organizations.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Small Business Ph.D./M.D./Other Professional Commercial Government Nonprofit Academic Institution
Abstract:	This FOA encourages investigator-initiated applications to develop new, high-priority research tools or techniques of high priority to the zebrafish community that will help exploit the power of the zebrafish as a vertebrate model for biomedical and behavioral research. Applications proposing tools or techniques that will enhance the ability to detect or characterize genes, proteins, molecules, and pathways of interest in development and aging, organ formation, neural processes, behavior, sensory processing, physiological processes, and disease processes are welcome. Objectives to be addressed in applications submitted in response to the FOA include, but are not limited to, the following: 1. Development and/or application of novel methods of mutagenesis (e.g., insertional, site-specific, conditional knockout vectors or systems) 2. Development of techniques supporting more efficient targeting of induced local lesions in genomes (TILLING) 3. Development of technologies for gene inactivation and for gene expression manipulation including, but not limited to, morpholino oligonucleotides, new types of antisense technology, techniques for homologous recombination, techniques for gene trapping, and strategies for directing gene misexpression, or other transgenic methodologies 4. Development of new genetic or genomic tools or technologies that are of high priority for the zebrafish community 5. Development of techniques or technologies for measuring or characterizing proteins or other important molecules in vivo However, applications that propose novel phenotyping methods or genetic screens will not be accepted in response to this FOA. Participating organizations include National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Cancer Institute (NCI), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), and National Institute of Neurological Disorders and Stroke (NINDS).
Contact Name:	Dr. Rebekah S. Rasooly
Contact Address:	Division of Kidney, Urologic, and Hematologic Diseases NIDDK/NIH Two Democracy Plaza 6707 Democracy Blvd., MSC 5458
Contact City:	Bethesda
Contact State:	Maryland
Contact Zip:	20892-5458
Contact Country:	United States
Contact Phone:	+1 (301) 594-6007
Contact Fax:	+1 (301) 480-3510
Contact Email:	rr185i@nih.gov
URL for more information:	http://grants1.nih.gov/grants/guide/pa-files/PAR-08-139.html
Date Last Revised:	April 9, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=113373
Keywords:	Animal Models
Sponsor Reference No:	PAR-08-139
Funding Type:	Research

COS Unique Id:	113390
Title:	In Utero Exposure to Bioactive Food Components and Mammary Cancer Risk (R21)
Sponsor:	Department of Health and Human Services (HHS) National Institutes of Health (NIH)
Sponsor Type:	Federal, U.S.
Deadline:	June 16, 2008 October 16, 2008 February 16, 2009
Deadline Note:	The opening date is May 16, 2008. This opportunity will expire on May 8, 2011.
Upper Amount:	$275,000
Amount Note:	This FOA utilizes the NIH Exploratory/Developmental Grant (R21) mechanism. The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. The R21 is not renewable. This program does not require cost sharing.
Eligibility:	Eligible applicants include institutions of higher education; nonprofits, for-profits, and small businesses; state governments; U.S. territories or possessions; regional organizations; non-domestic organizations; and eligible agencies of the federal government.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Small Business Ph.D./M.D./Other Professional Commercial Government Nonprofit Academic Institution
Abstract:	This FOA, issued by the National Cancer Institute (NCI), the National Institute of Environmental Health Sciences (NIEHS), and the Office of Dietary Supplements (ODS), is designed to promote research that will enhance the understanding of the relationship between exposures to bioactive food components and/or environmental chemicals in utero, hormonal and growth factor response, gene expression or epigenetic changes, and subsequent mammary cancer risk in preclinical models. Although much evidence suggests that dietary components are linked to cancer prevention, the specific nutrients, sites of action, and role of exposure in utero remain elusive. Similarly, there are data suggesting a role for environmental agents, such as mycotoxins, heterocyclic amines, and environmental chemicals with endocrine activity in the etiology of mammary cancer, but for which the doses, windows of susceptibility, and mechanisms are unclear. This FOA encourages applications that apply new high-throughput genomic, epigenomic, proteomic, and metabolomic technologies to determine how dietary exposures in utero influence adult breast cancer susceptibility. The resulting information will help define effective maternal dietary intervention strategies for breast cancer prevention in offspring. Using the NIH Exploratory/Developmental Grant (R21) funding mechanism, this FOA focuses on early and conceptual stages of research projects.
Contact Name:	Leslie Hickman, Grants Management Specialist
Contact Address:	National Cancer Institute Fairview Center Building, Suite 300 1003 West 7th Street
Contact City:	Frederick
Contact State:	Maryland
Contact Zip:	21701-4106
Contact Country:	United States
Contact Phone:	+1 (301) 846-1013
Contact Fax:	+1 (301) 451-5391
Contact Email:	HickmanL@mail.nih.gov
URL for more information:	http://grants1.nih.gov/grants/guide/pa-files/PA-08-141.html
Date Last Revised:	April 10, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=113390
Keywords:	Breast Cancer Cancer Prevention Environmental Medicine Pregnancy
Sponsor Reference No:	PA-08-141
Funding Type:	Research

COS Unique Id:	113394
Title:	In Utero Exposure to Bioactive Food Components and Mammary Cancer Risk (R01)
Sponsor:	Department of Health and Human Services (HHS) National Institutes of Health (NIH)
Sponsor Type:	Federal, U.S.
Deadline:	June 5, 2008 October 5, 2008 February 5, 2009
Deadline Note:	The opening date is May 5, 2008. This opportunity will expire on May 8, 2011.
Amount Note:	This FOA will utilize the NIH research project R01 grant mechanism. The total project period for an application submitted in response to this funding opportunity may not exceed five years. Applicants for an R01 award are not limited in dollars but need to reflect the actual needs of the proposed project. This program does not require cost sharing.
Eligibility:	Eligible applicants include institutions of higher education; nonprofits, for-profits, and small businesses; state governments; U.S. territories or possessions; regional organizations; non-domestic organizations; and eligible agencies of the federal government.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Small Business Ph.D./M.D./Other Professional Commercial Government Nonprofit Academic Institution
Abstract:	This FOA, issued by the National Cancer Institute (NCI), the National Institute of Environmental Health Sciences (NIEHS), and the Office of Dietary Supplements (ODS), is designed to promote research that will enhance the understanding of the relationship between exposures to bioactive food components and/or environmental chemicals in utero, hormonal and growth factor response, gene expression or epigenetic changes, and subsequent mammary cancer risk in preclinical models. Although much evidence suggests that dietary components are linked to cancer prevention, the specific nutrients, sites of action, and role of exposure in utero remain elusive. Similarly, there are data suggesting a role for environmental agents, such as mycotoxins, heterocyclic amines, and environmental chemicals with endocrine activity in the etiology of mammary cancer, but for which the doses, windows of susceptibility, and mechanisms are unclear. This FOA encourages applications that apply new high-throughput genomic, epigenomic, proteomic, and metabolomic technologies to determine how dietary exposures in utero influence adult breast cancer susceptibility. The resulting information will help define effective maternal dietary intervention strategies for breast cancer prevention in offspring. Using the NIH Research Project Grant (R01) funding mechanism, this FOA focuses on discrete, specified, circumscribed projects based upon strong preliminary data.
Contact Name:	Leslie Hickman, Grants Management Specialist
Contact Address:	National Cancer Institute Fairview Center Building, Suite 300 1003 West 7th Street
Contact City:	Frederick
Contact State:	Maryland
Contact Zip:	21701-4106
Contact Country:	United States
Contact Phone:	+1 (301) 846-1013
Contact Fax:	+1 (301) 451-5391
Contact Email:	HickmanL@mail.nih.gov
URL for more information:	http://grants1.nih.gov/grants/guide/pa-files/PA-08-140.html
Date Last Revised:	April 10, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=113394
Keywords:	Breast Cancer Cancer Prevention Environmental Medicine Pregnancy
Sponsor Reference No:	PA-08-140
Funding Type:	Research

COS Unique Id:	113421
Title:	Mitochondria in Cancer Epidemiology, Detection, Diagnosis, and Prognosis (R01)
Sponsor:	Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI)
Sponsor Type:	Federal, U.S.
Deadline:	June 5, 2008 October 5, 2008 February 5, 2009
Deadline Note:	The opening date is May 5, 2008. This opportunity will expire on May 8, 2011.
Amount Note:	This FOA will utilize the NIH research project R01 grant mechanism. The total project period for an application submitted in response to this funding opportunity may not exceed five years. Applicants for an R01 award are not limited in dollars but need to reflect the actual needs of the proposed project. This program does not require cost sharing.
Eligibility:	Eligible applicants include public and state-controlled institutions of higher education; private institutions of higher education; nonprofits, for-profits, and small businesses; state governments; U.S. territories or possessions; non-domestic organizations; regional organizations; and eligible agencies of the federal government.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Small Business Commercial Government Nonprofit Academic Institution
Abstract:	The purpose of this FOA is to stimulate the development and validation of novel mitochondrial (mt) DNA biomarkers for early detection, diagnosis, prognosis, and risk assessment of cancer. This FOA will stimulate research on either mutations in mtDNA and/or mitochondrial proteome analysis, for identification of additional indicators of tumor development and progression. Some of the specific questions that may be addressed in response to this FOA include, but are not limited to, the following: 1. Are mitochondrial genomic and proteomic profiles useful for identification of individuals who are at high-risk for cancer before clinical manifestation of disease? 2. Is an increased ratio of haplotypes within the mitochondrial genome associated with risk of developing cancer? If so, can these parameters help explain racial and ethnic differences in cancer risk? 3. Are there modifiable or host factors that can influence the correlation between mtDNA mutations, mitochondrial dysfunction, and cancer risk? 4. Are alterations in the mitochondrial genome and proteome associated with intermediate disease states in the neoplastic pathway, such as precursor lesions? 5. Are mtDNA alterations (such as somatic mutations and structural rearrangements including duplications and deletions) correlated with development of various cancers? 6. Can mutations or instability in mtDNA prognosticate specific types of tumorigenesis or malignant transformation? 7. How can mitochondrial markers be utilized to predict disease progression and identify novel therapeutic targets? The mitochondrial markers may comprise point mutations, deletions, amplifications, and SNPs; alterations in mitochondrial morphology/clustering; and nuclear proteins that affect mitochondrial function. 8. Can novel technology be developed for high-throughput analysis and imaging of mitochondrial clustering? 9. Are there unique mtDNA mutations associated with specific types of cancers? 10. Can mtDNA mutations be detected in pre-malignant lesions, such as prostate intraepithelial neoplasia (PIN)? 11. Can high throughput diagnostic assays that are based upon mtDNA mutations (or in combination with other markers), be developed for noninvasive detection and or monitoring of cancer? 12. Can nutrition or chemopreventive agents reduce mtDNA instability by regulating or enhancing the efficiency of mtDNA repair mechanisms? Using the NIH Research Project Grant (R01) funding mechanism, this FOA focuses on discrete, specified, circumscribed projects based upon strong preliminary data.
Contact Name:	Crystal Wolfrey
Contact Address:	Office of Grants Administration National Cancer Institute 6120 Executive Boulevard EPS Suite 243, MSC 7150
Contact City:	Bethesda
Contact State:	Maryland
Contact Zip:	20892-7150
Contact Country:	United States
Contact Phone:	+1 (301) 496-8634
Contact Fax:	+1 (301) 496-8601
Contact Email:	wolfreyc@mail.nih.gov
URL for more information:	http://grants1.nih.gov/grants/guide/pa-files/PA-08-143.html
Date Last Revised:	April 11, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=113421
Keywords:	Biomarkers Cancer Genetics Epidemiology
Sponsor Reference No:	PA-08-143
Funding Type:	Research

COS Unique Id:	113422
Title:	Mitochondria in Cancer Epidemiology, Detection, Diagnosis, and Prognosis (R21)
Sponsor:	Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI)
Sponsor Type:	Federal, U.S.
Deadline:	June 16, 2008 October 16, 2008 February 16, 2009
Deadline Note:	The opening date is May 16, 2008. This opportunity will expire on May 8, 2011.
Upper Amount:	$275,000
Amount Note:	This FOA utilizes the NIH Exploratory/Developmental Grant (R21) mechanism. The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. The R21 is not renewable. This program does not require cost sharing.
Eligibility:	Eligible applicants include public and state-controlled institutions of higher education; private institutions of higher education; nonprofits, for-profits, and small businesses; state governments; U.S. territories or possessions; non-domestic organizations; regional organizations; and eligible agencies of the federal government.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Small Business Commercial Government Nonprofit Academic Institution
Abstract:	The purpose of this FOA is to stimulate the development and validation of novel mitochondrial (mt) DNA biomarkers for early detection, diagnosis, prognosis, and risk assessment of cancer. This FOA will stimulate research on mutations in mtDNA for identification of additional indicators of tumor development and progression, including mitochondrial somatic mutations and mitochondrial haplogroups. Some of the specific questions that may be addressed in response to this FOA include, but are not limited to, the following: 1. Are mitochondrial markers useful for identification of individuals who are at high-risk for cancer before clinical onset? 2. Are mitochondrial characteristics or haplotypes associated with risk of developing cancer? If so, can these parameters help explain racial and ethnic differences in cancer risk? 3. Are there modifiable or host factors that can influence the relationship between mtDNA characteristics and cancer risk? 4. Are alterations in mitochondrial function correlated with intermediate disease state in the neoplastic pathway, such as precursor lesions? 5. Are genetic and mtDNA alterations (such as somatic mutations, deletions) correlated with cancer development? 6. Can mutations or instability in mtDNA prognosticate tumorigenesis or malignant transformation? 7. How can mitochondrial markers be utilized to predict disease progression and identify novel therapeutic targets? The mitochondrial markers may comprise point mutations, deletions, amplifications, and SNPs; alterations in mitochondrial morphology/clustering; and nuclear proteins that impact mitochondrial function 8. Can novel technology be developed for high-throughput analysis and imaging of mitochondrial clustering? 9. Are there unique mtDNA mutations associated with specific types of cancers? 10. Can mtDNA mutations be detected in pre-malignant lesions, such as prostate intraepithelial neoplasia (PIN)? 11. Can high throughput diagnostic assays that are based upon mtDNA mutations (or in combination with other markers) be developed for noninvasive detection and or monitoring of cancer? 12. Can nutrition or chemopreventive agents reduce mtDNA instability by regulating repair mechanisms? Using the NIH Exploratory/Developmental Grant (R21) funding mechanism, this FOA focuses on early and conceptual stages of research projects.
Contact Name:	Crystal Wolfrey
Contact Address:	Office of Grants Administration National Cancer Institute 6120 Executive Boulevard EPS Suite 243, MSC 7150
Contact City:	Bethesda
Contact State:	Maryland
Contact Zip:	20892-7150
Contact Country:	United States
Contact Phone:	+1 (301) 496-8634
Contact Fax:	+1 (301) 496-8601
Contact Email:	wolfreyc@mail.nih.gov
URL for more information:	http://grants1.nih.gov/grants/guide/pa-files/PA-08-144.html
Date Last Revised:	April 11, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=113422
Keywords:	Biomarkers Cancer Genetics Epidemiology
Sponsor Reference No:	PA-08-144
Funding Type:	Research

COS Unique Id:	184
Title:	Postdoctoral Research Fellowships
Sponsor:	Whitney Foundation, Helen Hay
Sponsor Type:	Private Foundation
Deadline:	July 15, 2008
Amount:	$43,000
Amount Note:	The fellowship is for a period of three years, contingent on performance satisfactory to the foundation's Scientific Advisory Committee. One- and two-year fellowships are not considered. The current stipend and expense allowance is $43,000 in the first year, $44,000 in the second year, and $45,000 in the third year. The annual research allowance of $2,500 is given to the fellow's laboratory to help defray research expenses, such as lab supplies, computers, health insurance, etc. Its use is wholly at the discretion of the fellow's supervisor, except that no part of it may be used for institutional overhead. There is a dependent child allowance of $1,000 per annum for each child. There is no allowance for a spouse.
Eligibility:	Candidates who hold, or are in the final stages of obtaining, the Ph.D., M.D., or equivalent degree and are seeking beginning postdoctoral training in basic biomedical research are eligible to apply for a fellowship. The foundation accepts applications from candidates who have no more than one year of postdoctoral research experience at the time of the deadline for submitting the application (July 16) and who have received a Ph.D. (or D.Phil. or equivalent) degree no more than two years before the deadline, or an M.D. degree no more than three years before the deadline. Fellowships may be awarded to U.S. citizens planning to work in laboratories either in the United States, Canada, or abroad and also to foreign nationals for research in laboratories in the United States only. The foundation expects that most applicants will be resident in North America at the time of application. Foreign students will need to obtain appropriate visa documentation, as required by U.S. Immigration. Applications from established scientists or advanced fellows will not be considered. The fellowships are for early postdoctoral training only. Clinical house-staff training does not count as "postdoctoral laboratory training." The foundation will not ordinarily consider applicants who plan tenure of the fellowship in the laboratory in which they have already received extensive predoctoral or postdoctoral training. The aim of the fellowship is to broaden postdoctoral training and experience, and a significant change of venue is advisable. Because the number of available fellowships is limited, the foundation does not make more than one award in any one year for training with a given supervisor, and in addition, will not support more than two fellows per laboratory at one time. Although the foundation accepts multiple applications from the same laboratory in the same funding year, the foundation urges supervisors to support only one application if possible.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Ph.D./M.D./Other Professional
Abstract:	The Helen Hay Whitney Foundation supports early postdoctoral research training in all basic biomedical sciences. To attain its ultimate goal of increasing the number of imaginative, well-trained and dedicated medical scientists, the foundation grants financial support of sufficient duration to help further the careers of young men and women engaged in biological or medical research. The foundation expects that fellowship training will be obtained in an academic setting. The selection of a commercial or industrial laboratory for the training experience is not acceptable.
Contact Address:	Helen Hay Whitney Foundation 20 Squadron Boulevard, Suite 630
Contact City:	New York
Contact State:	New York
Contact Zip:	10956
Contact Country:	United States
Contact Phone:	+1 (845) 639-6799
Contact Fax:	+1 (845) 639-6798/+1 (646) 304-7133
Contact Email:	hhwf@earthlink.net
URL for more information:	http://www.hhwf.org/HTMLSrc/ResearchFellowships.html
Date Last Revised:	April 7, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=184
Keywords:	Biological Sciences Biomedical Research (Multidisciplinary) Biomedical Research Training Health and Medicine
Funding Type:	Postdoctoral Award

COS Unique Id:	2793
Title:	Beckman Young Investigators (BYI) Program
Sponsor:	Beckman Foundation, Arnold and Mabel
Sponsor Type:	Private Foundation
Deadline:	October 1, 2008
Deadline Note:	All application materials, including reference letters, must be received before 5:00 P.M. PST on the deadline. Internal coordination required. No more than two candidates may apply from any one institution. If the foundation receives more than two applications from any one institution, only the first two received shall be considered for review. Institutions that submit more than two applications will be rejected in their entirety.
Upper Amount:	$300,000
Amount Note:	Projects are normally funded for a period of three years. Grants are normally in the range of $300,000 over the term of the project. The foundation does not provide for overhead or for indirect costs.
Eligibility:	The BYI program is open to persons with tenure-track appointments in academic and nonprofit institutions that conduct fundamental research in the chemical and life sciences. Candidates must be citizens or permanent residents of the United States at the time of application. The candidate should not have completed more than three full years in his or her tenure-track or other comparable independent research appointment. Regardless of eligibility under this rule, no individual may apply for a BYI award more than three times.
Citizenship or Residency:	United States
Activity Location:	Unrestricted
Requirements:	Ph.D./M.D./Other Professional Nonprofit Academic Institution
Abstract:	The Arnold and Mabel Beckman Foundation makes grants to nonprofit research institutions to promote research in chemistry and the life sciences, broadly interpreted, and particularly to foster the invention of methods, instruments, and materials that will open up new avenues of research in science. The BYI Program is intended to provide research support to the most promising young faculty members in the early stages of academic careers in the chemical and life sciences. Additional Contact: Kathlene Williams, Executive Assistant Arnold and Mabel Beckman Foundation P.O. Box 13219 Newport Beach, California 92658 Phone +1 (949) 721-2222 Fax +1 (949) 721-2225 k.williams@beckman-foundation.com
Contact Name:	Program Administrator
Contact Address:	Arnold and Mabel Beckman Foundation P.O. Box 13219
Contact City:	Newport Beach
Contact State:	California
Contact Zip:	92658
Contact Country:	United States
Contact Phone:	+1 (949) 721-2222
Contact Fax:	+1 (949) 721-2225
Contact Email:	beckmanprograms@yahoo.com
URL for more information:	http://www.beckman-foundation.com/byi_guides.html
Date Last Revised:	April 8, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=2793
Keywords:	Chemical Sciences Health and Medicine Life Sciences
Funding Type:	Training, Scholarship, or Fellowship Research

COS Unique Id:	61141
Title:	Target Identification in Lupus (TIL) Grant
Sponsor:	Alliance for Lupus Research (ALR)
Sponsor Type:	Other Nonprofit
Deadline:	July 15, 2008
Deadline Note:	The deadline is for submission of the full applications. The ALR requests that investigators submit a letter of intent (LOI) online no later than 5:00 P.M. (EST) on April 30, 2008. Submission of the LOI does not commit the investigator to submitting an application, and is not required for submitting a full application.
Upper Amount:	$500,000
Amount Note:	Each grant of up to $500,000 will be awarded for a two-year time frame. Grants will be activated on February 2, 2009. Funding for the initial two-year period will be made for up to $250,000 per year including indirect costs. A grant renewal application and a second round of peer review will be required before the two-year point for continued funding of the final two years of the project. If awarded, the second phase of a project may be funded for a maximum of two additional years for an amount determined during the peer review process. Indirect costs are not to exceed 8 percent of the total amount approved.
Eligibility:	Individuals with doctoral degrees (M.D., Ph.D., D.O., or equivalent) are eligible to apply. Scientific independence, as evidenced by direction of a research program or a publication record or other experience that establishes scientific leadership, is necessary to apply. The ALR does not impose geographic restrictions on its applicants and investigators working anywhere in the world are eligible and encouraged to apply. The ALR is willing to appropriately support research in industry or collaborations between academia and industry.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Ph.D./M.D./Other Professional
Abstract:	The ALR funds research that will accelerate the development of new treatments of lupus. As such, grant proposals should be innovative in direction and utilize state-of-the-art techniques. Fundamental studies in genetics, immunology, cell biology, and molecular biology to identify and characterize molecular systems must be oriented towards the development of drugs that would prevent and/or ameliorate clinical signs and symptoms of lupus. Additional Contact: Diomaris Gonzalez, Manager of Research Administration Phone +1 (212) 218-2840 or +1 (800) 867-1743 dgonzalez@lupusresearch.org
Contact Address:	Alliance for Lupus Research 28 West 44th Street, Suite 501
Contact City:	New York
Contact State:	New York
Contact Zip:	10036
Contact Country:	United States
Contact Phone:	+1 (212) 218-2840
Contact Fax:	+1 (212) 218-2848
Contact Email:	grant.administration@lupusresearch.org
URL for more information:	http://lupusresearch.org/research/TIL.html
Date Last Revised:	April 9, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=61141
Keywords:	Autoimmunity Lupus
Funding Type:	Research